
|Articles|June 1, 2001
5-FU cream formulation displays unique profile
Washington - The new 5-fluorouracil (5-FU) 0.5 percent topical cream (Carac) indicated for the treatment of actinic keratoses offers more targeted drug delivery along with the potential for a more favorable safety profile than a previously available formulation containing a 10-fold higher concentration of active ingredient, according to results from comparative studies presented at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











